Volume 2 Supplement 1

Second International Symposium on the Molecular Biology of Breast Cancer

Open Access

Heterogeneity in the clinical phenotype of TP53 mutations in breast cancer patients

  • J Alsner1,
  • M Yilmaz1,
  • P Guldberg2,
  • LL Hansen1 and
  • J Overgaard1
Breast Cancer Research20002(Suppl 1):P4.04

DOI: 10.1186/bcr109

Published: 12 March 2000

Full text

TP53 mutation is a strong independent marker for survival in breast cancer with some heterogeneity in the clinical phenotype of various types of mutations. Based on 315 patients with breast carcinoma, we suggest a new model for the differentiation of TP53 mutations. Although TP53 mutation in general was associated with aggressive tumour/patient characteristics, missense mutations outside any conserved or structural domain did not affect the clinical outcome (risk of disseminated disease and death). In contrast, patients with missense mutations affecting amino acids directly involved in DNA-or zinc-binding displayed a very aggressive clinical phenotype. Null mutations (including missense mutations disrupting the tetramerization domain) and the remaining missense mutations displayed an intermediate aggressive clinical phenotype. When patients were divided into 3 groups, (i) wild-type together with the missense mutations outside structural/conserved domains, (ii) null mutations and the missense with intermediate clinical phenotype, and (iii) the very aggressive missense mutations, disease-specific survival rates were 89%, 58%, and 35% (5-year actuarial values, P < 0.0001), respectively. In a Cox proportional hazards analysis, separation of TP53 mutations according to these criteria eliminated the prognostic importance of all investigated classical factors except nodal status.

Authors’ Affiliations

(1)
Aarhus University Hospital
(2)
Danish Cancer Society

Copyright

© Current Science Ltd 2000

Advertisement